Literature DB >> 21893056

The mechanisms of microgliosis and pain following peripheral nerve injury.

Margarita Calvo1, David L H Bennett.   

Abstract

Microglia are the resident macrophages in the central nervous system (CNS). Any insult to the CNS homeostasis will induce a rapid change in microglia morphology, gene expression profile and functional behaviour. These responses of microglia have been collectively known as 'microgliosis'. Interestingly, damage to the nervous system outside the CNS, such as axotomy of a peripheral nerve, can lead to microgliosis in the spinal cord. There is a variation in the degree of microgliosis depending on the model of nerve injury employed for instance this response is more marked following traumatic nerve injury than in models of chemotherapy induced neuropathy. Following peripheral nerve injury nociceptive inputs from sensory neurons appear to be critical in triggering the development of spinal microgliosis. A number of signalling pathways including growth factors such as Neuregulin-1, matrix metalloproteases such as MMP-9 and multiple chemokines enable direct communication between injured primary afferents and microglia. In addition, we describe a group of mediators which although not demonstrably shown to be released from neurons are known to modulate microglial phenotype. There is a great functional diversity of the microglial response to peripheral nerve injury which includes: Cellular migration, proliferation, cytokine release, phagocytosis, antigen presentation and recruitment of T cells. It should also be noted that in certain contexts microglia may have a role in the resolution of neuro-inflammation. Although there is still no direct evidence demonstrating that spinal microglia have a role in neuropathic pain in humans, these patients present a pro-inflammatory cytokine profile and it is a reasonable hypothesis that these cells may contribute to this inflammatory response. Modulating microglial functions offers a novel therapeutic opportunity following nerve injury which ideally would involve reducing the pro-inflammatory nature of these cells whilst retaining their potential beneficial functions. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21893056     DOI: 10.1016/j.expneurol.2011.08.018

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  74 in total

1.  Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord.

Authors:  Sarah Taves; Temugin Berta; Da-Lu Liu; Sophie Gan; Gang Chen; Yong Ho Kim; Thomas Van de Ven; Stefan Laufer; Ru-Rong Ji
Journal:  Brain Behav Immun       Date:  2015-10-19       Impact factor: 7.217

Review 2.  Osteoarthritis pain: What are we learning from animal models?

Authors:  Rachel E Miller; Anne-Marie Malfait
Journal:  Best Pract Res Clin Rheumatol       Date:  2018-04-26       Impact factor: 4.098

Review 3.  Peripheral nerve injury modulates neurotrophin signaling in the peripheral and central nervous system.

Authors:  Mette Richner; Maj Ulrichsen; Siri Lander Elmegaard; Ruthe Dieu; Lone Tjener Pallesen; Christian Bjerggaard Vaegter
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

Review 4.  Crosstalk between the nociceptive and immune systems in host defence and disease.

Authors:  Stephen B McMahon; Federica La Russa; David L H Bennett
Journal:  Nat Rev Neurosci       Date:  2015-07       Impact factor: 34.870

5.  Pain in cancer survivors.

Authors:  Matthew Rd Brown; Juan D Ramirez; Paul Farquhar-Smith
Journal:  Br J Pain       Date:  2014-11

6.  Evidence for brain glial activation in chronic pain patients.

Authors:  Marco L Loggia; Daniel B Chonde; Oluwaseun Akeju; Grae Arabasz; Ciprian Catana; Robert R Edwards; Elena Hill; Shirley Hsu; David Izquierdo-Garcia; Ru-Rong Ji; Misha Riley; Ajay D Wasan; Nicole R Zürcher; Daniel S Albrecht; Mark G Vangel; Bruce R Rosen; Vitaly Napadow; Jacob M Hooker
Journal:  Brain       Date:  2015-01-12       Impact factor: 13.501

7.  Bilateral activation of glial cells and cellular distribution of the chemokine CCL2 and its receptor CCR2 in the trigeminal subnucleus caudalis of trigeminal neuropathic pain model.

Authors:  Lucie Kubíčková; Ilona Klusáková; Petr Dubový
Journal:  Histochem Cell Biol       Date:  2020-02-04       Impact factor: 4.304

8.  Granulocyte-Macrophage Colony Stimulating Factor As an Indirect Mediator of Nociceptor Activation and Pain.

Authors:  Damini Tewari; Andrew D Cook; Ming-Chin Lee; Anne D Christensen; Andrew Croxford; Burkhard Becher; Daniel Poole; Pradeep Rajasekhar; Nigel Bunnett; Julia E Smith; John A Hamilton; Stephen B McMahon
Journal:  J Neurosci       Date:  2020-02-04       Impact factor: 6.167

9.  Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain.

Authors:  Amanda Ellis; Julie Wieseler; Jacob Favret; Kirk W Johnson; Kenner C Rice; Steven F Maier; Scott Falci; Linda R Watkins
Journal:  J Pain       Date:  2014-01-09       Impact factor: 5.820

10.  Effects of spinal non-viral interleukin-10 gene therapy formulated with d-mannose in neuropathic interleukin-10 deficient mice: Behavioral characterization, mRNA and protein analysis in pain relevant tissues.

Authors:  Arden G Vanderwall; Shahani Noor; Melody S Sun; Jacob E Sanchez; Xuexian O Yang; Lauren L Jantzie; Nikolaos Mellios; Erin D Milligan
Journal:  Brain Behav Immun       Date:  2017-11-04       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.